Invention Grant
- Patent Title: Modified effector cell (or chimeric receptor) for treating disialoganglioside GD2-expressing neoplasia
-
Application No.: US14354082Application Date: 2012-10-25
-
Publication No.: US10647997B2Publication Date: 2020-05-12
- Inventor: Massimo Dominici , Sara Caldrer , Maria Carlotta Spano , Paolo Paolucci , Marco Bestagno , Dario Campana
- Applicant: Massimo Dominici , Sara Caldrer , Maria Carlotta Spano , Paolo Paolucci , Marco Bestagno , Dario Campana
- Applicant Address: US TN Memphis
- Assignee: St. Jude Children's Research Hospital, Inc.
- Current Assignee: St. Jude Children's Research Hospital, Inc.
- Current Assignee Address: US TN Memphis
- Agency: Themis Law
- Agent Franco A. Serafini; David M. Fortner
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@7f573c35
- International Application: PCT/IB2012/055878 WO 20121025
- International Announcement: WO2013/061273 WO 20130502
- Main IPC: C12N15/85
- IPC: C12N15/85 ; A61K35/17 ; C07K14/705 ; C07K14/47 ; C07K16/42 ; C07K16/30
Abstract:
A modified effector cell includes a non-reversibly produced vector-encoded anti-GD2-BB-ζ chimeric receptor for use in disialoganglioside GD2-expressing neoplasia, which is inserted in the cell, to obtain an effector cell that stably produces the anti-GD2-BB-ζ chimeric receptor, the chimeric receptor having two distinct mutually fused portions, i.e. an intra-cytoplasmic portion and an extra-cytoplasmic portion.
Public/Granted literature
- US20140302608A1 Modified Effector Cell (or Chimeric Receptor) for Treating Disialoganglioside GD2-Expressing Neoplasia Public/Granted day:2014-10-09
Information query
IPC分类:
